Fennec Pharmaceuticals Inc.
FENCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 12, 2026 | Wedbush | $16.00(+35%) | $11.88 | TheFly | |
| May 22, 2026 | H.C. Wainwright | $16.00(+60%) | $9.97 | TheFly | |
| Jan 8, 2026 | Piper Sandler | $18.00(+137%) | $7.58 | TheFly | |
| Aug 15, 2025 | Craig-Hallum | Chase Knickerbocker | $14.00(+64%) | $8.54 | TheFly |
| May 15, 2024 | Craig-Hallum | Chase Knickerbocker | $17.00(+132%) | $7.34 | TheFly |
| May 15, 2024 | H.C. Wainwright | Raghuram Selvaraju | $15.00(+113%) | $7.03 | StreetInsider |
| Apr 4, 2024 | H.C. Wainwright | Raghuram Selvaraju | $18.00(+67%) | $10.77 | TheFly |
| Mar 19, 2024 | Craig-Hallum | Chase Knickerbocker | $18.00(+63%) | $11.01 | StreetInsider |
| Nov 22, 2022 | Cantor Fitzgerald | $12.00(+31%) | $9.17 | Benzinga | |
| Sep 26, 2022 | Wedbush | $19.00(+167%) | $7.11 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 9, 2026 |
| B. Riley Securities | maintain | Buy | Aug 12, 2026 |
| Wedbush | maintain | Outperform | Aug 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 22, 2026 |
| Wedbush | maintain | Outperform | Apr 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 21, 2025 |
| Craig-Hallum | maintain | Buy | Aug 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 20, 2025 |
| Craig-Hallum | maintain | Buy | May 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 22, 2024 |
| Craig-Hallum | maintain | Buy | Aug 14, 2024 |
| Craig-Hallum | maintain | Buy | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2024 |
| Craig-Hallum | maintain | Buy | Mar 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 21, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Apr 6, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jan 26, 2023 |
| Cantor Fitzgerald | upgrade | Neutral →Overweight | Nov 22, 2022 |
| HC Wainwright & Co. | maintain | Buy | Oct 20, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $0.05 | $0.02 | $17.9M | $16.2M |
| May 14, 2026 | $0.01 | $-0.02 | $15.1M | $13.9M |
| Mar 24, 2026 | $-0.17 | $0.03 | $13.8M | $14.7M |
| Nov 13, 2025 | $-0.02 | $-0.08 | $12.5M | $14.7M |
| Aug 14, 2025 | $-0.11 | $-0.06 | $9.7M | $9.6M |
| May 13, 2025 | $-0.04 | $-0.12 | $8.8M | $9.0M |
| Mar 10, 2025 | $-0.06 | $0.56 | $7.9M | $7.8M |
| Nov 7, 2024 | $-0.21 | $-0.13 | $7.0M | $8.0M |
News
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, November 12, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The
Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Analyst Recommendations This is a summary of recent
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.